CD274 and non-small cell lung carcinoma: Notably, in the phase III MYSTIC trial, the combination of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) could not improve OS against chemotherapy in PD-L1 ≥ 25% first-line advanced NSCLC (31).